Cite
Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment
MLA
Sara E. Mole, et al. “Cerebrospinal Fluid Neurofilament Light Levels in CLN2 Disease Patients Treated with Enzyme Replacement Therapy Normalise after Two Years on Treatment.” F1000Research, vol. 10, July 2021, p. 614. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........2bb564316030f63398369a48f862c8ea&authtype=sso&custid=ns315887.
APA
Sara E. Mole, Henrik Zetterberg, Katharina Iwan, Laura M. Lee, Nina Patel, Mina Borisova, Paul Gissen, Amanda Heslegrave, Wendy E. Heywood, Philippa B. Mills, Kevin Mills, & Rebecca Bower. (2021). Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 10, 614.
Chicago
Sara E. Mole, Henrik Zetterberg, Katharina Iwan, Laura M. Lee, Nina Patel, Mina Borisova, Paul Gissen, et al. 2021. “Cerebrospinal Fluid Neurofilament Light Levels in CLN2 Disease Patients Treated with Enzyme Replacement Therapy Normalise after Two Years on Treatment.” F1000Research 10 (July): 614. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........2bb564316030f63398369a48f862c8ea&authtype=sso&custid=ns315887.